CAS 49763-96-4
:Estiripentol
- (1E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ol
- 1-(1,3-Benzodioxol-5-Yl)-4,4-Dimethylpent-1-En-3-Ol
- 1-(1,3-Benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol
- 1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-
- 256-480-9
- 4,4-Dimethyl-1-(3,4-methylenedioxyphenyl)-1-penten-3-ol
- Bcx 2600
- Diacomit
- Stiripentol
1-(Benzo[d][1,3]Dioxol-5-Yl)-4,4-Dimethylpent-1-En-3-Ol
CAS:1-(Benzo[d][1,3]Dioxol-5-Yl)-4,4-Dimethylpent-1-En-3-OlPureza:99%Peso molecular:234.29g/molStiripentol
CAS:Fórmula:C14H18O3Pureza:≥ 98.0%Cor e Forma:White to off-white powder or solidPeso molecular:234.29Stiripentol
CAS:Fórmula:C14H18O3Pureza:>98.0%(GC)Cor e Forma:White to Almost white powder to crystalPeso molecular:234.30Stiripentol
CAS:Stiripentol (BCX2600) (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediated by CYP3A4 (noncompetitively) and CYP2C19 (Fórmula:C14H18O3Pureza:99.87% - >99.99%Cor e Forma:White SolidPeso molecular:234.29Stiripentol
CAS:Produto ControladoApplications An epilepsy drug. It has been used as co-therapy for treatment of epilepsy. It inhibits the enzymes responsible for metabolism of other anti-convulsant agents.
References Laurie, D., et al.: J. Neurosci., 12, 4151 (1992), Smith, A., et al.: J. Pharmacol. Exp. Therap., 311, 601 (2004), Trojnar, M., et al.: Pharm. Rep., 57, 154 (2005), Drafts, B., et al.: J. Pharm. Exp. Ther., 318, 1094 (2006), Picton, A., et al.: Brain Res., 1165, 40 (2007),Fórmula:C14H18O3Cor e Forma:Light Yellow SolidPeso molecular:234.294,4-Dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol
CAS:4,4-Dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol is a drug that has been used in the treatment of Dravet syndrome. This drug is also known as 3,4-methylenedioxyphenylacetone. It is a competitive inhibitor of the enzyme citrate synthase and inhibits the conversion of acetate to citrate. The effect of 4,4-dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol on sodium citrate concentrations is concentration dependent and results in an increase in plasma sodium concentrations with prolonged administration. Other drugs that are metabolized by the cytochrome P450 system may interact with 4,4-dimethyl-1-[(3,4 methylenedioxy)phenyl]-1 penten 3 ol and lead to increased levels of these drugs in the blood.
Fórmula:C14H18O3Pureza:Min. 95%Cor e Forma:White PowderPeso molecular:234.29 g/mol








